AnaCardio

📍 Solna, Sweden👥 26 employees💰 Last funded Jun 2026
Biotechnology Research🌐 anacardio.com
Website LinkedIn
AnaCardio AB is a privately held clinical stage biopharmaceutical company developing novel drugs to treat heart failure. AnaCardio was founded based on ground-breaking research from Karolinska Institutet showing improved contractility of the heart muscle through a unique and differentiated mechanism. The Company’s lead program AC01, a first-in-class calcium sensitizing inotrope, is an oral ghrelin mimetic small-molecule, which was in-licensed from Helsinn and is now being developed as a contractile agent in heart failure patients. The company has raised over USD 40 million to date. AnaCardio is based in Stockholm, Sweden. You can find more information about AnaCardio at www.anacardio.com.
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
Sweden
2
United States
1
Investor activity2022–2026 · investors recorded per year
202212025120261
Recent (last 2y)Earlier
Frequently asked questions
Who invested in AnaCardio?
AnaCardio has 3 investors on record on gritt.io.
When did AnaCardio last raise funding?
The most recent investment in AnaCardio recorded on gritt.io was in June 2026.
What industry is AnaCardio in?
AnaCardio operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is AnaCardio based?
AnaCardio is headquartered in Solna, Sweden.